89 related articles for article (PubMed ID: 8502476)
1. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry.
Hassapoglidou S; Diamandis EP; Sutherland DJ
Oncogene; 1993 Jun; 8(6):1501-9. PubMed ID: 8502476
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
3. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
4. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
5. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
7. p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease.
Katoh A; Breier S; Stemmler N; Specht S; Blanock K; D'Amico F
Anticancer Res; 1996; 16(3A):1301-4. PubMed ID: 8702254
[TBL] [Abstract][Full Text] [Related]
8. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.
Bonsing BA; Corver WE; Gorsira MC; van Vliet M; Oud PS; Cornelisse CJ; Fleuren GJ
Cytometry; 1997 May; 28(1):11-24. PubMed ID: 9136751
[TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors.
Landberg G; Ostlund H; Nielsen NH; Roos G; Emdin S; Burger AM; Seth A
Oncogene; 2001 Jun; 20(27):3497-505. PubMed ID: 11429696
[TBL] [Abstract][Full Text] [Related]
11. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2.
Cano G; Milanezi F; Leitão D; Ricardo S; Brito MJ; Schmitt FC
Diagn Cytopathol; 2003 Oct; 29(4):207-11. PubMed ID: 14506673
[TBL] [Abstract][Full Text] [Related]
12. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
13. Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting.
Liu Y; Asch H; Kulesz-Martin MF
Cancer Res; 2001 Jul; 61(14):5402-6. PubMed ID: 11454683
[TBL] [Abstract][Full Text] [Related]
14. Tumor growth fraction, expression of estrogen and progesterone receptors, p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary lymph node metastases.
Kristek J; Dmitrović B; Kurbel S; Sakić K; Krajinović Z; Blazicević V; Has B; Marjanović K
Coll Antropol; 2007 Dec; 31(4):1043-7. PubMed ID: 18217456
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical analysis of heat shock protein 70, p53, and estrogen receptor status in carcinoma of the uterine cervix.
Park CS; Joo IS; Song SY; Kim DS; Bae DS; Lee JH
Gynecol Oncol; 1999 Jul; 74(1):53-60. PubMed ID: 10385551
[TBL] [Abstract][Full Text] [Related]
16. p21(WAF1) expression and endocrine response in breast cancer.
McClelland RA; Gee JM; O'Sullivan L; Barnes DM; Robertson JF; Ellis IO; Nicholson RI
J Pathol; 1999 Jun; 188(2):126-32. PubMed ID: 10398154
[TBL] [Abstract][Full Text] [Related]
17. The association between telomerase activity and hormone receptor status and p53 expression in breast cancer.
Mokbel K; Ghilchik M; Williams G; Akbar N; Parris C; Newbold R
Int J Surg Investig; 2000; 1(6):509-16. PubMed ID: 11729859
[TBL] [Abstract][Full Text] [Related]
18. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells.
Ogretmen B; Safa AR
Oncogene; 1997 Jan; 14(4):499-506. PubMed ID: 9053847
[TBL] [Abstract][Full Text] [Related]
19. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.
Yousef GM; Polymeris ME; Grass L; Soosaipillai A; Chan PC; Scorilas A; Borgoño C; Harbeck N; Schmalfeldt B; Dorn J; Schmitt M; Diamandis EP
Cancer Res; 2003 Jul; 63(14):3958-65. PubMed ID: 12873991
[TBL] [Abstract][Full Text] [Related]
20. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
